Photo from wikipedia
Despite improvements in left ventricular assist device (LVAD) technology, survival rates have remained stagnant over the past decade. 1 – 6 Adverse events continue to impede wider expansion of this… Click to show full abstract
Despite improvements in left ventricular assist device (LVAD) technology, survival rates have remained stagnant over the past decade. 1 – 6 Adverse events continue to impede wider expansion of this life ‐ saving therapy. 1 Right ventricular failure (RVF) post ‐ LVAD, in particular, portends very poor outcomes, 1,7 – 11 with right ventricular assist device (RVAD) requirement associated with a threefold to fourfold increase in mortality. 1 Management of RVF focuses on preoperative risk assessment and patient selection, postoperative inotropic and pulmonary vasodilator support, and RVAD implantation in severe cases. Methods to mitigate against its occurrence are lacking. 7 – 13 may through
Journal Title: Journal of Cardiac Surgery
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!